Return to Main Site 617-919-3019
401 Park Drive, 7th Floor East, Boston, MA 02215

TIDO Technology Search



Invention Type

Diagnostic/Prognostic
Information Technology/Software
Medical Device
Other
Research Tool
Therapeutics

Research Area

Allergy/Respiratory/Pulmonary Disease
Anesthesia
Audiology
Cardiovascular/Cardiology
Degenerative Disease
Dermatology
Endocrinology
Gastrointestinal/Nutrition
Genetic Disease
Health Care Management
Immunology
Infectious Disease
Inflammation
Internal Medicine
Metabolic Disease
Musculoskeletal
Neonatology/Pediatric
Neurology/Neuroscience
Oncology/Hematology
Ophthalmology
Orthopedics
Otolaryngology/Audiology
Pain
Pathology
Personalized Medicine
Psychiatric Disease
Radiology
Regenerative Medicine
Reproduction/Ob-Gyn
Stem Cell
Surgery/Wound Healing
Urology
CMCC 1337

Urine Biomarkers for Bladder Cancer

Inventors: Bruce Zetter, Adam Feldman, Scott McDougal

Invention Types: Diagnostic/Prognostic

Research Areas: Oncology/Hematology, Urology

Keywords: Biomarker

For More Information Contact:  Dietz, Ryan

 

Invention Description:

Bladder cancer is the second most common genitourinary cancer in the US. While 70% of new cases present as tumors without invasion into the muscularis propria, up to 50-70% of those cases will recur after resection and 10-20% will progress to a more invasive form of the disease. There remains a critical need to identify molecular markers that will allow for better prediction of which patients will recur and progress to metastatic disease.


Using proteomics and antibody-based approaches, Dr. Zetter and colleagues found elevated levels of cystatin B, a cathepsin protease inhibitor, in bladder cancer tissue as well as a correlation between urinary cystatin B levels and transitional cell carcinoma (TCC) grade/stage. Cathepsin proteases are known to be increased in various cancers and cystatin B protein levels have been demonstrated to correlate with tumor presence and stage in other cancers. Multivariate analysis that controlled for tumor grade, stage, multifocality, and subsequent BCG therapy confirmed that urinary cystatin B is a highly significant predictor of disease grade/stage progression in TCC.

Applications:

Cystatin B is a clinically useful prognostic marker for bladder cancer.

Competitive Advantages:

• Cystatin B as a biomarker may improve the ability to predict which patients will develop invasive, metastatic disease and allow for more personalized treatments

• Compared to other clinicopathologic data, cystatin B is a highly significant predictor of early disease recurrence and progression

Business Opportunity:

Collaboration and licensing opportunities available

Key Publications: Feldman et al., 2009. Cystatin B as a tissue and urinary biomarker of bladder cancer recurrence and disease progression. Clinical Cancer Research 15(3): 1024-1031 | US patent #8,685,659 issued, EPO issued #1842065

IPStatus: Patented